Loading...
•
Dec 31, 2021
Organogenesis Q4 2021 Earnings Report
Organogenesis reported strong Q4 2021 financial results, with a 20% increase in net revenue and a 28% increase on an adjusted basis.
Key Takeaways
Organogenesis Holdings Inc. reported a 20% increase in net revenue for Q4 2021 compared to Q4 2020. Net income also increased significantly, and the company provided financial guidance for fiscal year 2022.
Net revenue for Q4 2021 was $128.6 million, a 20% increase year-over-year.
Advanced Wound Care products revenue increased by 30% compared to Q4 2020.
Net income for Q4 2021 was $51.7 million, compared to $18.3 million in Q4 2020.
Adjusted EBITDA for Q4 2021 was $26.3 million, compared to $24.9 million in Q4 2020.
Organogenesis
Organogenesis
Organogenesis Revenue by Segment
Revenue by Segment
Advanced Wound Care Revenue
CapyFin.com Forward Guidance
For the year ending December 31, 2022, the Company expects net revenue of between $485 million and $515 million, representing an increase of approximately 4% to 10% year-over-year, and 6% to 13% on an adjusted basis, as compared to net revenue of $468.1 million for the year ended December 31, 2021.
Positive Outlook
- Net revenue of between $485 million and $515 million, representing an increase of approximately 4% to 10% year-over-year, and 6% to 13% on an adjusted basis
- Net revenue from Advanced Wound Care products of between $455 million and $481 million, representing an increase of approximately 6% to 12% year-over-year
- Net revenue from the sale of PuraPly products of between $207 million and $217 million, representing an increase of approximately 4% to 9% year-over-year
- Net income of between $56.5 million and $71.5 million
- EBITDA of between $73.5 million and $88.9 million
Challenges Ahead
- Net revenue from Surgical & Sports Medicine products of between $30 million and $34 million, representing a decrease of approximately 9% to 19% year-over-year
- Changes to reimbursement levels for the Company’s products
- Significant and continuing competition
- Rapid technological change could cause the Company’s products to become obsolete
- COVID-19 pandemic and its impact, if any, on the Company’s fiscal condition and results of operations